ClinicalTrials.gg
RecruitingNCT01670695Updated Apr 11, 2017

A Prospective Cohort Study of IgG4RD in China

An observational study in IgG4-related Disease, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-11.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2012; still recruiting 14 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.

Started
2012
with 2 others
Observational
4 of 15
3 open now
Registered
2nd of 15
by date

Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one is one of 3 that started in 2012, is one of 4 observational ones, and was the 2nd registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.

Read the detailed description

Immunoglobulin G4-related disease (IgG4-RD) is a recently defined emerging clinical entity characterized by tissue infiltration by IgG4-positive plasma cells, tissue fibrosclerosis and elevated serum IgG4 concentration.

In this study, patients with IgG4-RD will be investigated, including clinical presentation, laboratory findings and imaging study. All patients will be treated by standard care and follow-uped for at least 6 months.

03

Conditions studied

  • IgG4-related Disease

Keywords

  • IgG4-related disease
  • IgG4-RD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with newly diagnosed IgG4-related disease.

Eligibility criteria

Inclusion Criteria:

  • Males and females
  • Age 18-75 years old with
  • Patients with IgG4-RD:

    1. swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions;
    2. elevated serum IgG4 (>1.35 g/L)
    3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma cell infiltration (and IgG4+ plasma cells on immunohistology when performed);
    4. exclusion of other diseases.

Exclusion Criteria:

  • Females planning to bear a child recently or with
  • Concurrent severe and/or uncontrolled and/or unstable diseases
  • Patient with
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • IgG4-RD

    Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.

06

What researchers measure

Primary outcomes

  1. Clinical Response

    Clinical Response is measured by IgG4-RD Responder Index, including organ/site score and serum IgG4 level.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Deptment of Rheumatology, Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
    Recruiting
08

References and documents

Publications

  • Luo X, Peng Y, Zhang P, Li J, Liu Z, Lu H, Zhang X, Zeng X, Zhang F, Fei Y, Zhang W. Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study. Front Med (Lausanne). 2020 Jul 7;7:253. doi: 10.3389/fmed.2020.00253. eCollection 2020. PubMed 32733900 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2012 (actual). Primary completion is estimated for Jan 2032, 240 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2012
First posted
Aug 22, 2012
StartActual
Jan 2012
Primary completionEst.
Jan 2032
CompletionEst.
Jan 2032
Last update
Apr 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01670695
Responsible party
Wen Zhang (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Aug 22, 2012
Start date
Jan 2012
Primary completion
Jan 2032 (estimated)
Completion
Jan 2032 (estimated)
Last update
Apr 11, 2017

Study contacts

Hua Chen, MD
Contact
chen77hua@gmail.com
86-10-69158797
Wen Zhang, MD
principal investigator · Deptment of Rheumatology, Peking Union Medical College Hospital
Fengchun Zhang
study chair · Deptment of Rheumatology, Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion